Massive study reveals Semaglutide's Heart-Protective power in obesity
NCT ID NCT07141914
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a once-weekly medicine called semaglutide (used for weight loss and diabetes) can lower the risk of heart attacks, strokes, and death in people with overweight or obesity. Researchers analyzed medical records of over 285,000 people in the US. The goal was to see if semaglutide helps prevent major heart problems in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novo Nordisk Investigational
Plainsboro, New Jersey, 08536, United States